Jia Qian-Nan, Qiao Ju, Fang Kai, Zeng Yue-Ping
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.
Front Med (Lausanne). 2022 Mar 3;9:802036. doi: 10.3389/fmed.2022.802036. eCollection 2022.
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin disorders. Dupilumab, the first targeted biological drug approved for the treatment of AD, has been widely used, along with increasing ocular adverse effects (AEs).
To perform a bibliometric analysis of all the qualified literature involving ocular AEs during the treatment of AD with dupilumab.
Relevant studies were extracted from the Web of Science database and screened by researchers. The bibliographic analysis was performed using the VOSviewer.
A total of 138 articles were enrolled in this study. The first study was published in 2016 by Oregon Health and Science University from the United States. The majority of publications were published in the past 3 years. published the highest number of articles. The United States was the country with the most publications. Sanofi (France) and Regeneron Pharmaceuticals (USA) were the leading organizations with the most contributions. Conjunctivitis was the most common ocular AE. The management of AD will continue to be the research hotspot and development trend in this area. The milestone research is the first article "Two Phase 3 Trials of Dupilumab vs. Placebo in Atopic Dermatitis" published in the . Most of the top 10 papers were mainly randomized, placebo-controlled phase 2 and phase 3 clinical trials and real-life large cohort studies.
This study may help better understand ocular AEs in the dupilumab treatment of AD, and grasp the research trends and most influential topics in this field.
特应性皮炎（AD）是最常见的慢性炎症性皮肤病之一。度普利尤单抗是首个被批准用于治疗AD的靶向生物药物，随着其使用的增加，眼部不良反应（AE）也日益增多。
对所有涉及度普利尤单抗治疗AD期间眼部AE的合格文献进行文献计量分析。
从Web of Science数据库中提取相关研究，并由研究人员进行筛选。使用VOSviewer进行文献计量分析。
本研究共纳入138篇文章。第一项研究于2016年由美国俄勒冈健康与科学大学发表。大多数出版物发表于过去3年。发表文章数量最多。美国是发表文章最多的国家。赛诺菲（法国）和再生元制药公司（美国）是贡献最大的领先机构。结膜炎是最常见的眼部AE。AD的管理将继续是该领域的研究热点和发展趋势。具有里程碑意义的研究是发表在……上的第一篇文章《度普利尤单抗与安慰剂治疗特应性皮炎的两项3期试验》。排名前十的论文大多主要是随机、安慰剂对照的2期和3期临床试验以及真实世界的大型队列研究。
本研究可能有助于更好地了解度普利尤单抗治疗AD时的眼部AE，并掌握该领域的研究趋势和最具影响力的主题。
